RxDoctor Payments Data

Lindsay Songer, APRN

Psychiatric/Mental Health · Radcliff, KYNPI 1558098855

Payments from drug & device makers

$2,535in general payments, 2019–2025

Across 129 payments — averaging $19.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$652
  • Axsome Therapeutics, Inc.$387
  • Novo Nordisk$199
  • Corium, LLC$177
  • Neurocrine Biosciences, Inc.$159
  • Takeda Pharmaceuticals U.S.A., Inc.$117
  • plus $844 from 23 others

What the payments were for

  • Food & beverage$2,50899%
  • Education$281%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,535 in reported general payments places this provider in the 75th percentile of 946 psychiatric/mental health providers in Kentucky.

See all psychiatric/mental health providers in Kentucky

Medicare billing

Part B allowed, 2024
$37,992
Medicare patients
59
Services billed
440

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl38$59,747
RexultiBrexpiprazole13$18,799
TrintellixVortioxetine Hydrobromide30$17,175
Lurasidone Hcl23$6,974
Bupropion XlBupropion Hcl153$2,199
Aripiprazole89$1,800
Quetiapine Fumarate61$1,661
Mirtazapine127$1,373
Duloxetine Hcl143$1,299
Buspirone Hcl79$1,065
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine19$672
Prazosin Hcl69$665
Desvenlafaxine Succinate ErDesvenlafaxine Succinate15$633
Temazepam17$587
Vilazodone Hcl18$528

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$652$59,74738 claims
Otsuka America Pharmaceutical, Inc.Rexulti$94$18,79913 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$117$17,17530 claims
Lilly USA, LLCOlanzapine$61$30519 claims
Almatica Pharma LLCSertraline Hcl$39$18040 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 946 psychiatric/mental health providers in Kentucky.

Other psychiatric/mental health in Radcliff

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →